Survodutide

Survodutide is an investigational peptide therapeutic being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. It is classified as a long-acting, dual-receptor agonist.

Its mechanism of action involves the simultaneous activation of both the Glucagon-like peptide-1 (GLP-1) receptor and the Glucagon (GCG) receptor. The GLP-1 receptor agonism provides potent effects on glycemic control and appetite suppression, while the concurrent glucagon receptor activation is designed to increase energy expenditure and specifically enhance the metabolism of fat within the liver. The therapeutic hypothesis is that this dual action will lead to substantial weight loss and a direct improvement in liver health.

Survodutide is in late-stage Phase 3 clinical trials for obesity as of June 2025. It has garnered significant attention for its promising results in treating MASH, for which it has received Breakthrough Therapy Designation from the FDA, highlighting its potential to address a critical unmet need in liver disease.